ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the activity of the combination ZD1839,
docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer by
estimating the objective response rate (complete response [CR] and partial response [PR]) at
study closure.